PeptideDB
de
EnglishEspañolDeutschPortuguês
PeptideKategorienVergleichLeitfädenGlossar

Cagrilintide

Umfassend untersucht

Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes

GewichtsverlustMetabolisch

Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes.

Molekulare und Forschungsdaten

Sequenz
37-amino acid peptide
Molekulargewicht
4,409.01 Da
Halbwertszeit
~7 days (159-195 hours)
Primäre Ziele
amylin-receptor
Wege (Forschung)
injectable
Lagerung
Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use within 30 days

Overview

Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination.

Mechanism of action

Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. Enhances insulin sensitivity and controls gastric emptying.

Key research findings

  • FDA development candidate with extensive Phase 3 data
  • Superior weight loss in combination with semaglutide (22.7%)
  • Once-weekly convenience
  • 2.2% HbA1c reduction with CagriSema

Research applications

Weight Loss

  • Obesity (Monotherapy) — Phase 3 trials demonstrate significant weight loss.
  • Obesity (CagriSema Combination) — 22.7% weight loss with CagriSema combination, surpassing existing therapies.
  • Weight Loss in Diabetic Patients — 15.7% weight loss in diabetic patients with concurrent glycemic improvements.

Metabolic

  • Glycemic Control — 2.2% HbA1c reduction with CagriSema versus semaglutide alone.
  • Insulin Sensitivity — Amylin receptor activation enhances insulin sensitivity and glucose metabolism.

Appetite Control

  • Satiety Enhancement — Dual pathway satiety via amylin and calcitonin receptor activation.

Cagrilintide Häufig gestellte Fragen

How much weight loss can I expect from CagriSema combination therapy?+

Phase 3 REDEFINE trials showed estimated mean weight loss of -20.4% at 68 weeks without diabetes vs -3% placebo. In diabetic patients, CagriSema achieved -13.7% weight loss vs -3.4% placebo. These are the most dramatic weight loss results seen with any approved or experimental therapy to date.

Why do 46-73% of people develop anti-cagrilintide antibodies, and does it matter?+

Anti-cagrilintide antibodies develop in roughly half of users, likely due to the peptide being foreign. Remarkably, clinical trial data showed these antibodies do NOT reduce efficacy—weight loss continues despite antibody formation. This unusual finding suggests the antibodies don't significantly neutralize the therapeutic effect.

Why is pH so critical when reconstituting cagrilintide?+

Cagrilintide's peptide structure is prone to fibril formation and aggregation at neutral pH. Maintaining pH 3.5-4.5 prevents this self-assembly into inactive clumps. Solution must remain clear; any cloudiness or particles indicate degradation, and the dose should be discarded to avoid injecting aggregated, potentially less potent or harmful material.

When will cagrilintide be available and can I get it now?+

Cagrilintide is not yet commercially available. FDA approval is expected Q1 2026. Current access is limited to clinical trial participants. Anyone claiming to sell cagrilintide now is offering an unapproved, likely research-grade product of unknown quality and purity.

References

  1. [1]Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine
  2. [2]Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 DiabetesNew England Journal of Medicine
  3. [3]Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trialThe Lancet
  4. [4]CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1Hypertension
  5. [5]CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditureMolecular Metabolism

Verwandte Peptide

5-Amino-1MQ

Preclinical

NNMT Inhibitor | Longevity & Metabolic Enhancement

5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function.

LanglebigkeitMetabolischGewichtsverlust

AOD-9604

Well studied

Modified hGH Fragment | Fat Loss Peptide

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone.

GewichtsverlustMetabolisch

BAM-15

Moderate research

Mitochondrial Uncoupler | Metabolic Enhancer

BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders.

GewichtsverlustMetabolisch

HGH Fragment 176-191

Moderate research

Growth Hormone Fragment | Fat Loss Peptide

HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule.

GewichtsverlustMetabolisch